SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix shares are under significant downward pressure following mixed second-quarter results and light third-quarter revenue guidance, fueling investor concerns that the company's growth phase is moderating. While the community is sharply divided between those calling the pullback a generational buying opportunity bolstered by record share repurchases and those pointing to subscriber fatigue and perceived content failures as signs of a structural decline.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently facing significant downward pressure as investors react to a scrubbed Starship test flight and anticipation of upcoming insider lock-up expirations. The community is sharply divided, with some investors viewing the price decline as a buying opportunity in a long-term sector leader, while others are warning of continued volatility and calling for lower entry points as they question the company's valuation.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing intense volatility and a significant technical correction as investors debate whether the recent decline is a long-term bubble burst or a temporary reset in the memory sector. The community remains deeply polarized, with many retail traders highlighting massive paper losses while others argue that secular demand for AI and datacenter storage provides a fundamental buying opportunity for long-term holders.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is facing significant selling pressure as investors rotate out of high-growth semiconductor stocks following concerns about AI valuation bubbles and cooling market sentiment. While some market participants see the sharp price decline as a potential bargain, many community members remain skeptical, pointing to the stock's massive drawdown from its recent highs and intense debate over its long-term viability versus speculative hype.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as the stock surges to new all-time highs, driven by investor optimism surrounding the rollout of AI features in the Chinese market and its potential to reclaim the title of the world's most valuable company. The community remains deeply divided, with bulls pointing to ecosystem strength and AI integration as catalysts for a generational run, while vocal bears argue the current valuation is decoupled from growth fundamentals and driven by manipulative market mechanics.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is currently facing intense selling pressure and high volatility, with the community actively debating whether the decline represents a major buying opportunity or the bursting of an AI-related bubble. Investors remain divided, as many are focused on the long-term potential of the company's AI infrastructure and recent partnerships, while others worry about valuation concerns, potential margin liquidations, and the impact of broader sector rotation.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is facing intense volatility as market participants debate whether the recent sharp pullback is a buying opportunity or the end of the AI-driven memory supercycle. The community remains deeply divided, with many traders pointing to strong fundamental demand and low forward valuations as reasons to hold, while skeptics are increasingly concerned about potential margin liquidations, geopolitical headwinds, and the exhaustion of momentum.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending as investors debate whether the current drawdown is a fundamental repricing or a temporary shakeout driven by broader rotation out of high-beta AI infrastructure stocks. The community is actively parsing news about data center demand and hyperscaler capital spending while holding for earnings and monitoring institutional positioning.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is facing intense volatility as investors weigh the long-term potential of its massive AI infrastructure backlog against concerns over debt, regulatory moratoriums, and heavy insider selling. While the community is deeply divided between those viewing the pullback as a generational buying opportunity and those fearing a fundamental overvaluation, active discussion remains focused on critical support levels and the sustainability of high-growth AI infrastructure business models.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as investors digest a strong earnings beat and raised full-year guidance that signal a stabilization in medical costs and margin pressure. The community is actively discussing the stock's resilient recovery and its role as a defensive leader as market sentiment shifts toward sector rotation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$GALT Against my better judgement, I bought at $4.95 after a recommendation from a colleague in the low $5&#39;s.  Now down to the low 4&#39;s.  Any hope here?  Strictly a BO/PS/M&amp;A trade or real value here?  Is this another $ALT 2.0 or what are we legitimately looking at here? Bear/Bull feedback appreciated. 
 
Cheers!

ThomasLD

Ollie cooper

John Harter

StockTwits Web

Galectin Therapeutics Inc

Altimmune Inc

 Against my better judgement, I bought at $4.95 after a recommendation from a colleague in the low $5's.  Now down to the low 4's.  Any hope here?  Strictly a BO/PS/M&A trade or real value here?  Is this another 

 2.0 or what are we legitimately looking at here? Bear/Bull feedback appreciated. 
 
Cheers!

The Legendary Mayor

StockTwits for iOS

Marlin

@BioRich If you can afford it, I would buy more and average down.  This should bounce on any real news and the science is good.  The problem is most of the neebies here are not patient.  And I could be wrong.

"Schuuultz!"

StockTwits For Android 

 If you can afford it, I would buy more and average down.  This should bounce on any real news and the science is good.  The problem is most of the neebies here are not patient.  And I could be wrong.

Robert Kaplan

@BioRich there is a legitimate reason to hold here. Received positive FDA feedback basically green light to proceed with Phase III. IMO BO at this point is not likely, but a partnership should happen now within the next couple months. I&#39;m anticipating a price action to be around $18-$20 if they announce a strong partnership. They have a billionaire chairman that could carry this alone through Phase III, but dilution would be horrendous. Easy for me to hold because I rebought in the low $2&#39;s so up over 100% still. Been a holder and trading this since 2017. This company is in a strong spot right now the price action is kind of hard to ignore when it drops a lot, but it jumped past $5 this week on a new powerpoint presentation so its a bit volatile.

straightforward

Jeffery Rachford

 there is a legitimate reason to hold here. Received positive FDA feedback basically green light to proceed with Phase III. IMO BO at this point is not likely, but a partnership should happen now within the next couple months. I'm anticipating a price action to be around $18-$20 if they announce a strong partnership. They have a billionaire chairman that could carry this alone through Phase III, but dilution would be horrendous. Easy for me to hold because I rebought in the low $2's so up over 100% still. Been a holder and trading this since 2017. This company is in a strong spot right now the price action is kind of hard to ignore when it drops a lot, but it jumped past $5 this week on a new powerpoint presentation so its a bit volatile.

BiggerT

@BioRich check this out then look at the valuation of the company now. If you can afford it then I would put more shares in your bags.

https://investor.galectintherapeutics.com/static-files/1f768e5c-133f-436e-9da4-834668e80ae7

Galectintherapeutics

 check this out then look at the valuation of the company now. If you can afford it then I would put more shares in your bags.



BullsOnParade

@BioRich  Ok Rich. You need to understand the TAM, F4 cirrhosis with CSPH. In the US alone, there are 3.3 M pts that fit this category. This is a patient stage that is not F4c(MDGL) 250K coded US pts or potentially SGMT (that is waiting for a partner) You can bone up on portal hypertension biology to see that these are the patients most at risk of decompensating, &amp; there are no FDA approved treatments.  Different than AKRO that enrolls an earlier stage.  Based on GALT;s last PR, The framework now is set for the partnership and or BO, and  would refer you to Kilarck&#39;s message on this that u can go ahead and stress test. This is not ALT or IVA that has to compete with AKRO MDGL, NOVO and Lilly already in the game for F2/F3. The bull case here is very compelling but only for those who can see the forest through the trees, and its my largest holding.

Guy Craig

Jack

Anonymous

Jim Tucker

  Ok Rich. You need to understand the TAM, F4 cirrhosis with CSPH. In the US alone, there are 3.3 M pts that fit this category. This is a patient stage that is not F4c(MDGL) 250K coded US pts or potentially SGMT (that is waiting for a partner) You can bone up on portal hypertension biology to see that these are the patients most at risk of decompensating, & there are no FDA approved treatments.  Different than AKRO that enrolls an earlier stage.  Based on GALT;s last PR, The framework now is set for the partnership and or BO, and  would refer you to Kilarck's message on this that u can go ahead and stress test. This is not ALT or IVA that has to compete with AKRO MDGL, NOVO and Lilly already in the game for F2/F3. The bull case here is very compelling but only for those who can see the forest through the trees, and its my largest holding.

Expharmaguy

@BullsOnParade79 Thanks for the link/insight.  Gives me ALT PTSD.  Has a lot of the same feels and I may need to look back at the presentation but wasn&#39;t a fan of the n-numbers and p-values.  Again, I don&#39;t want to go down a negative path, but I&#39;m just not feeling it.  Also, financing?  And when could they expect completion of the trial?  We&#39;re looking at a long road and I think this sees 3&#39;s before 7s.  I&#39;m replaying directly to you as I recall the name.  And I&#39;m not looking for any tickers to be Bearish on and am certainly not looking to find flaws in the GALT (or mess with the board).

 Thanks for the link/insight.  Gives me ALT PTSD.  Has a lot of the same feels and I may need to look back at the presentation but wasn't a fan of the n-numbers and p-values.  Again, I don't want to go down a negative path, but I'm just not feeling it.  Also, financing?  And when could they expect completion of the trial?  We're looking at a long road and I think this sees 3's before 7s.  I'm replaying directly to you as I recall the name.  And I'm not looking for any tickers to be Bearish on and am certainly not looking to find flaws in the GALT (or mess with the board).